Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
215,820

+2.51 (2.97%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $86.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View

Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.

    Pacira (PCRX) Posts Earnings in Q4, Revenues in Line

    Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.

      Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress

      Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.

        Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat

        Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.

          Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y

          Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.

            Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down

            Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.

              Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y

              Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.

                Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y

                Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.

                  AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues

                  AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.

                    Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid

                    Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.

                      What's in Store for Ligand (LGND) This Earnings Season?

                      Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.

                        Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

                        Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

                          Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                            Medicines Company to Sell Infectious Disease Unit to Melinta

                            The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.

                              Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

                              GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

                                Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

                                The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

                                  Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

                                  Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.

                                    Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

                                    Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.

                                      AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

                                      AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

                                        Biogen Acquires Worldwide License for Alkermes' MS Candidate

                                        Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

                                          AstraZeneca Files for Label Expansion of Tagrisso in Japan

                                          AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

                                            Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

                                            Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

                                              Spectrum Doubles in 3 Months: What's Driving the Rally?

                                              Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.

                                                Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

                                                Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

                                                  Puma Inks License Deal to Commercialize Cancer Drug Nerlynx

                                                  Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.